中国医学前沿杂志(电子版)
中國醫學前沿雜誌(電子版)
중국의학전연잡지(전자판)
CHINESE JOURNAL OF THE FRONTIERS OF MEDICAL SCIENCE(ELECTRONIC VERSION)
2015年
7期
122-125
,共4页
王丽强%杨秀婷%林思彤%玄延花
王麗彊%楊秀婷%林思彤%玄延花
왕려강%양수정%림사동%현연화
食管癌%放疗%化疗%深部热疗
食管癌%放療%化療%深部熱療
식관암%방료%화료%심부열료
Esophageal cancer%Radiation therapy%Chemotherapy%Deep hyperthermia
目的:探析放化疗联合深部热疗治疗胸段食管癌的近期和远期效果,并评价其安全性。方法将本院2010年4月至2012年3月确诊并收治的86例胸段食管癌患者随机分为研究组和对照组,每组各43例。对照组患者采用放化疗联合治疗,研究组在对照组基础上应用深部热疗。对比两组患者近期疗效、远期疗效及治疗期间不良反应发生情况。结果研究组患者显效率为88.37%(38/43),显著高于对照组[65.12%(28/43)](P<0.05)。研究组患者治疗总有效率为100.00%(43/43),对照组为90.70%(39/43),两组比较差异无显著性(P>0.05)。两组均无失访病例。研究组患者生存率、局部复发率及癌灶扩散率分别为62.79%、25.58%、25.58%,对照组分别为51.16%、27.91%、32.56%,两组比较差异均无显著性(P>0.05)。两组患者骨髓抑制、放射性食管炎、放射性肺炎、放射性皮炎、恶心呕吐、肝肾功能损伤发生率比较差异均无显著性(P>0.05)。结论放化疗联合深部热疗可显著提高胸段食管癌近期临床疗效,且不会增加治疗本身所产生的不良反应,具有显著的临床应用价值,但对食管癌的远期疗效无明显提升作用。
目的:探析放化療聯閤深部熱療治療胸段食管癌的近期和遠期效果,併評價其安全性。方法將本院2010年4月至2012年3月確診併收治的86例胸段食管癌患者隨機分為研究組和對照組,每組各43例。對照組患者採用放化療聯閤治療,研究組在對照組基礎上應用深部熱療。對比兩組患者近期療效、遠期療效及治療期間不良反應髮生情況。結果研究組患者顯效率為88.37%(38/43),顯著高于對照組[65.12%(28/43)](P<0.05)。研究組患者治療總有效率為100.00%(43/43),對照組為90.70%(39/43),兩組比較差異無顯著性(P>0.05)。兩組均無失訪病例。研究組患者生存率、跼部複髮率及癌竈擴散率分彆為62.79%、25.58%、25.58%,對照組分彆為51.16%、27.91%、32.56%,兩組比較差異均無顯著性(P>0.05)。兩組患者骨髓抑製、放射性食管炎、放射性肺炎、放射性皮炎、噁心嘔吐、肝腎功能損傷髮生率比較差異均無顯著性(P>0.05)。結論放化療聯閤深部熱療可顯著提高胸段食管癌近期臨床療效,且不會增加治療本身所產生的不良反應,具有顯著的臨床應用價值,但對食管癌的遠期療效無明顯提升作用。
목적:탐석방화료연합심부열료치료흉단식관암적근기화원기효과,병평개기안전성。방법장본원2010년4월지2012년3월학진병수치적86례흉단식관암환자수궤분위연구조화대조조,매조각43례。대조조환자채용방화료연합치료,연구조재대조조기출상응용심부열료。대비량조환자근기료효、원기료효급치료기간불량반응발생정황。결과연구조환자현효솔위88.37%(38/43),현저고우대조조[65.12%(28/43)](P<0.05)。연구조환자치료총유효솔위100.00%(43/43),대조조위90.70%(39/43),량조비교차이무현저성(P>0.05)。량조균무실방병례。연구조환자생존솔、국부복발솔급암조확산솔분별위62.79%、25.58%、25.58%,대조조분별위51.16%、27.91%、32.56%,량조비교차이균무현저성(P>0.05)。량조환자골수억제、방사성식관염、방사성폐염、방사성피염、악심구토、간신공능손상발생솔비교차이균무현저성(P>0.05)。결론방화료연합심부열료가현저제고흉단식관암근기림상료효,차불회증가치료본신소산생적불량반응,구유현저적림상응용개치,단대식관암적원기료효무명현제승작용。
ObjectiveTo explore the short-term and long-term therapeutic effect and evaluate the security of radiation therapy and chemotherapy combined with deep hyperthermia in the treatment of thoracic esophageal cancer.Method86 patients with thoracic esophageal cancer diagnosed and treated in our hospital from April 2010 to March 2012 were randomly divided into research group and control group, 43 cases in each group. Control group were given chemotherapy combined with radiotherapy. On the basis of research group were given deep hyperthermia. The short-term and long-term therapeutic effect, adverse reactions were compared between the two groups.ResultThe efifciency rate of research group was 88.37%(38/43), significantly higher than control group [65.11% (28/43)] (P<0.05). The total effective rate of research group was 100.00% (43/43), control group was 90.70% (39/43), the difference was not signiifcant (P>0.05). There was no patient lost to follow up in both groups. The survival rate, local recurrence rate and diffusibility of cancer in research group were 62.79%, 25.58% and 25.58% respectively, while control group were 51.16%, 27.91% and 32.56% respectively, the differences were not signiifcant between the two groups (P>0.05). There was no signiifcant difference in the incidence of myelosuppression, radiation esophagitis, radiation pneumonitis, radiodermatitis, nausea and vomiting and hepatic and renal function damage between the two groups (P>0.05).ConclusionThe chemoradiotherapy combined with the deep hyperthermia in the treatment of thoracic esophageal cancer can significantly improve the short-term clinical effect and not significantly increase the adverse reaction, with the obvious clinical value; but it has no significant improvement on the long-term effect.